A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.
Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 milligram (mg) of mirikizumab as reference formulation \[100 mg/milliliter (mL)\], 2 × 1-mL autoinjector administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.
Drug: Mirikizumab
200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL autoinjector administered as a SC injection into the arm/thigh/abdomen on day 1.
Drug: Mirikizumab
Administered SC.
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
PK: Cmax of mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab
PK: AUC\[0-∞\] of Mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab
PK: AUC\[0-tlast\] of Mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
| Milestone | 200 Milligram (mg) Mirikizumab (Reference): Abdomen | 200 mg Mirikizumab (Reference): Arm | 200 mg Mirikizumab (Reference): Thigh | 200 mg Mirikizumab (Test): Abdomen | 200 mg Mirikizumab (Test): Arm | 200 mg Mirikizumab (Test): Thigh |
|---|---|---|---|---|---|---|
| Started | 63 | 69 | 67 | 66 | 66 | 65 |
| Received at least 1 dose of study drug | 63 | 69 | 67 | 66 | 66 | 65 |
| Completed | 62 | 66 | 65 | 65 | 64 | 64 |
| Not completed | 1 | 3 | 2 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
PK: Cmax of mirikizumab was evaluated.
| micrograms per milliliter (μg/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab | 13.0 ± 42 | 12.9 ± 40 |
PK: AUC\[0-∞\] of Mirikizumab was evaluated.
| microgram*day per milliliter (μg*day/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab | 229 ± 43 | 232 ± 42 |
PK: AUC\[0-tlast\] of Mirikizumab was evaluated.
| μg*day/mL | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab | 225 ± 42 | 231 ± 41 |
Collected over Baseline Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Mirikizumab (Reference): Abdomen | 0/63 (0%) | 0/63 (0%) | 11/63 (17.5%) |
| 200 mg Mirikizumab (Reference): Arm | 0/69 (0%) | 0/69 (0%) | 12/69 (17.4%) |
| 200 mg Mirikizumab (Reference): Thigh | 0/67 (0%) | 0/67 (0%) | 13/67 (19.4%) |
| 200 mg Mirikizumab (Test): Abdomen | 0/66 (0%) | 0/66 (0%) | 7/66 (10.6%) |
| 200 mg Mirikizumab (Test): Arm | 0/66 (0%) | 0/66 (0%) | 11/66 (16.7%) |
| 200 mg Mirikizumab (Test): Thigh | 0/65 (0%) | 0/65 (0%) | 12/65 (18.5%) |
| Event | 200 mg Mirikizumab (Reference): Abdomen | 200 mg Mirikizumab (Reference): Arm | 200 mg Mirikizumab (Reference): Thigh | 200 mg Mirikizumab (Test): Abdomen | 200 mg Mirikizumab (Test): Arm | 200 mg Mirikizumab (Test): Thigh |
|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 10/63 | 10/69 | 12/67 | 4/66 | 6/66 | 9/65 |
| HeadacheNervous system disorders | 2/63 | 4/69 | 2/67 | 3/66 | 7/66 | 3/65 |
All randomized participants.
| Age, Continuous(years) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Mean | 40.7 ± 13.0 | 41.1 ± 12.2 | 40.9 ± 12.6 |
| Sex: Female, Male(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Female | 98 | 104 | 202 |
| Male | 101 | 93 | 194 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Hispanic or Latino | 36 | 33 | 69 |
| Not Hispanic or Latino | 163 | 164 | 327 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 6 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 29 | 30 | 59 |
| White | 150 | 152 | 302 |
| More than one race | 9 | 9 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| United States | 199 | 197 | 396 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Feb 2023, 5 months.
Results were first posted in Jul 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab